Reference
1. Cicenas J, Cicenas E. Multi-kinase inhibitors, AURKs and cancer. Med Oncol. 2016;33(5):43.
2. Fukuda N, Takahashi S. Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. Cancers (Basel). 2021;13(9).
3. Elsherbeny MH, Elkamhawy A, Nada H, Abdellattif MH, Lee K, Roh EJ. Development of New Meridianin/Leucettine-Derived Hybrid Small Molecules as Nanomolar Multi-Kinase Inhibitors with Antitumor Activity. Biomedicines.2021;9(9).
4. Raoul JL, Edeline J, Simmet V, Moreau-Bachelard C, Gilabert M, Frenel JS. Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. Cancers (Basel).2022;14(5).
5. Zhang L, Wu F, Lee SC, Zhao H, Zhang L. pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development. Clin Pharmacol Ther. 2014;96(2):266-277.
6. Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41(5):412-422.
7. Kletzl H, Giraudon M, Ducray PS, Abt M, Hamilton M, Lum BL. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.Anticancer Drugs. 2015;26(5):565-572.
8. Pape E, Michel D, Scala-Bertola J, et al. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia.Br J Clin Pharmacol. 2016;81(6):1195-1196.
9. Zhou A, Zhang W, Chang C, et al. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemother Pharmacol. 2013;72(5):1043-1053.
10. Mu X, Ma J, Zhang Z, et al. Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation.Int J Radiat Biol. 2015;91(9):771-776.
11. Zhang W, Zhou AP, Qin Q, et al. Famitinib in metastatic renal cell carcinoma: a single center study.Chin Med J (Engl). 2013;126(22):4277-4281.
12. Qu YY, Zhang HL, Guo H, et al. Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study. Clin Cancer Res. 2021;27(21):5838-5846.
13. Zhang M, Quan H, Fu L, Li Y, Fu H, Lou L. Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells. Thorac Cancer. 2021;12(8):1210-1218.
14. Qu YY, Sun Z, Han W, et al. Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study. J Immunother Cancer. 2022;10(5).
15. Chen Q, Tang L, Liu N, et al. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study. Cancer Commun (Lond).2018;38(1):66.
16. Chen L, Jiang YZ, Wu SY, et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial. Clin Cancer Res. 2022.
17. Xia L, Peng J, Lou G, et al. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. J Immunother Cancer. 2022;10(1).
18. Thomas T. Camrelizumab plus famitinib to treat RCC. Nat Rev Urol. 2021;18(10):576.
19. Xu RH, Shen L, Wang KM, et al. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chin J Cancer.2017;36(1):97.
20. Ge S, Zhang Q, He Q, et al. Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts. Oncol Lett. 2016;12(3):1763-1768.
21. Xie C, Zhou J, Guo Z, et al. Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol.2013;168(7):1687-1706.
22. Smelick GS, Heffron TP, Chu L, et al. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm. 2013;10(11):4055-4062.
23. Raoul JL, Guerin-Charbonnel C, Edeline J, Simmet V, Gilabert M, Frenel JS. Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer. JAMA Netw Open.2021;4(6):e2113739.
24. Lozano I, Sanchez-Insa E, de Leiras SR, et al. Acute Coronary Syndromes, Gastrointestinal Protection, and Recommendations Regarding Concomitant Administration of Proton-Pump Inhibitors (Omeprazol/Esomeprazole) and Clopidogrel. Am J Cardiol. 2016;117(3):366-368.
Tables
Table 1 Summary of pharmacokinetic parameter analysis of famitinib and SHR116637